Aravive Reports Preliminary Results of AVB-500 from the First Cohort of the Phase 1b/Phase 2 Recurrent Platinum Resistant Ovarian Cancer Trial July 31, 2019 - NASDAQ Companies 0 » View More News for July 31, 2019
